Akari Therapeutics (AKTX) Accounts Payables (2011 - 2026)

Akari Therapeutics (AKTX) has 16 years of Accounts Payables data on file, last reported at $8.6 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 33.87% year-over-year to $8.6 million; the trailing twelve-month figure through Mar 2026 stood at $8.6 million (down 33.87% YoY), and the FY2025 full-year result was $8.8 million, down 29.31% from the prior year.
• Accounts Payables retreated to $8.6 million in Q1 2026, from $8.8 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $13.1 million in Q1 2025 to a low of $947000.0 in Q4 2022.
• A 5-year average of $7.3 million and a median of $8.6 million in 2026 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables plunged 47.05% in 2022 and surged 642.49% in 2024, its largest moves.
• Tracing AKTX's Accounts Payables over 5 years: stood at $947000.0 in 2022, then jumped by 76.45% to $1.7 million in 2023, then surged by 642.49% to $12.4 million in 2024, then dropped by 29.31% to $8.8 million in 2025, then retreated by 1.47% to $8.6 million in 2026.
• Business Quant data shows AKTX's Accounts Payables at $8.6 million in Q1 2026, $8.8 million in Q4 2025, and $10.8 million in Q3 2025.